Last updated September 10, 2026
Key finding
At Week 24, the least squares (LS) mean change in HbA1c from baseline was -1.12% (95% CI -1.24 to -1.01) with HS-IDegAsp.
The study compared HS-IDegAsp and NN-IDegAsp in Chinese patients with T2DM, finding comparable efficacy and safety profiles.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study compared HS-IDegAsp and NN-IDegAsp in Chinese patients with T2DM, finding comparable efficacy and safety profiles.
Understanding the efficacy and safety of different insulin regimens is crucial for optimizing diabetes management. This study provides evidence that HS-IDegAsp is as effective as NN-IDegAsp, offering healthcare providers more options for treating patients with T2DM in China.
The study's sample size may limit the generalizability of findings. Results are specific to the Chinese population and may not apply elsewhere. The study duration of 24 weeks may not capture long-term effects.
Published in
Publication details and source links for this paper.
Leili G, Zhifeng C, Guoqing M, et al. HS-IDegAsp demonstrated comparable efficacy and safety to NN-IDegAsp in Chinese patients with T2DM. Journal of Diabetes Investigation. 2025;17(1):42-50. doi:10.1111/jdi.70175
HS-IDegAsp reduced HbA1c by -1.12% (95% CI -1.24 to -1.01).
NN-IDegAsp reduced HbA1c by -1.23% (95% CI -1.34 to -1.11).
No significant difference in fasting plasma glucose between groups (P > 0.05).
26.5% of HS-IDegAsp patients achieved HbA1c < 7.0% compared to 32.8% of NN-IDegAsp patients (P = 0.2089).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to HS-IDegAsp, NN-IDegAsp and Fasting Plasma Glucose (FPG), HbA1c, Proportion achieving HbA1c <7.0%.
This study contributes evidence to
Primary intervention
HS-IDegAsp
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
6
Evidence pairs
1489
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
HS-IDegAsp → Fasting Plasma Glucose (FPG)
HS-IDegAsp → Fasting Plasma Glucose (FPG)
HS-IDegAsp → Proportion achieving HbA1c <7.0%
HS-IDegAsp → Proportion achieving HbA1c <7.0%
NN-IDegAsp → Fasting Plasma Glucose (FPG)
NN-IDegAsp → Fasting Plasma Glucose (FPG)
NN-IDegAsp → Proportion achieving HbA1c <7.0%
NN-IDegAsp → Proportion achieving HbA1c <7.0%
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on HS-IDegAsp and Fasting Glucose, HS-IDegAsp and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on HS-IDegAsp
Contributes to HS-IDegAsp evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
HS-IDegAsp appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
NN-IDegAsp appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of HS-IDegAsp for fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of HS-IDegAsp for proportion achieving HbA1c <7.0%.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Proportion achieving HbA1c <7.0%
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
